HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Dianthus Therapeutics (NASDAQ:DNTH) and maintained a $40 price target.
August 12, 2024 | 6:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Dianthus Therapeutics and maintained a $40 price target.
The reiteration of a Buy rating and the maintenance of a $40 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100